4.3 EFFECT OF LURASIDONE ON BODY WEIGHT AND LABORATORY PARAMETERS IN ADOLESCENT PATIENTS WITH SCHIZOPHRENIA: RESULTS FROM A 6-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

Objectives: To evaluate the effect of short-term treatment with lurasidone on body weight, metabolic parameters, and prolactin levels in adolescent patients with schizophrenia. Methods: In a multicenter, placebo-controlled study, adolescents (13-17 years old) with schizophrenia (DSM-IV-TR criteria)...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American Academy of Child and Adolescent Psychiatry 2016-10, Vol.55 (10), p.S163-S163
Hauptverfasser: Goldman, Robert S., PhD, Robb, Adelaide S., MD, Silva, Robert M., PhD, Cucchiaro, Josephine B., PhD, Deng, Ling, PhD, Loebel, Antony, MD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page S163
container_issue 10
container_start_page S163
container_title Journal of the American Academy of Child and Adolescent Psychiatry
container_volume 55
creator Goldman, Robert S., PhD
Robb, Adelaide S., MD
Silva, Robert M., PhD
Cucchiaro, Josephine B., PhD
Deng, Ling, PhD
Loebel, Antony, MD
description Objectives: To evaluate the effect of short-term treatment with lurasidone on body weight, metabolic parameters, and prolactin levels in adolescent patients with schizophrenia. Methods: In a multicenter, placebo-controlled study, adolescents (13-17 years old) with schizophrenia (DSM-IV-TR criteria) were randomly assigned to 6 weeks of double-blind treatment with fixed-dose lurasidone 40 mg/d, 80 mg/d, or placebo. Safety analyses included change from baseline to week 6 in body weight (mixed-model repeated-measures analysis) and laboratory parameters (rank analysis ofcovariance [ANCOVA] with the last observation carried forward[LOCF]). Results: A total of 326 patients (mean age=15.4 years) were randomized and received lurasidone 40 mg/d (N=108), 80 mg/d (N=106), or placebo (N=112). Least-squares mean change in weight at week 6 for the lurasidone 40 mg/d, 80 mg/d, and placebo groups was 0.17 kg, 0.49 kg, and 0.05 kg, respectively. Median change at week 6 (LOCF) in total cholesterol (overall) was -4.0 mg/dL, -2.0 mg/dL, and -7.0 mg/dL, respectively; in triglycerides was -2.0 mg/dL, 7.0 mg/dL, and -2.0 mg/dL, respectively; and in glucose was 0.0 mg/dL, 1.0 mg/dL, and 0.0 mg/dL, respectively. Median change in prolactin level at week 6 (LOCF) in male patients was 0.8 ng/mL, 1.0 ng/mL, and 0.0 ng/mL for the lurasidone 40 mg/d, 80 mg/d, and placebo groups, respectively; and in female patients was 0.6 ng/mL, 4.4 ng/mL, and 0.7 ng/mL, respectively. Conclusions: Lurasidone was not associated with clinically meaningful effects on body weight, lipids, glucose, or prolactin in this placebo-controlled trial involving adolescent patients with acute schizophrenia. These findings require confirmation in longer-term studies, they but provide support for the safety of lurasidone as a potential treatment for adolescents with schizophrenia. Longer-term, open-label safety data are currently being collected.
doi_str_mv 10.1016/j.jaac.2016.09.198
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1850768271</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0890856716314277</els_id><sourcerecordid>1850768271</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2121-2f1597d1cff197610e10a66152f351fdf45c2e41e374980c31770712bac696963</originalsourceid><addsrcrecordid>eNp9ks-K2zAQxk1poem2L9CToJce1q5G_iO7lIJiKxtTrRVsh5BehKvI4NSb7Fqbwr5Sn7IKKRT2UHQYwfy-YWa-8bz3gAPAkHzaB_uu0wFx_wBnAWTpC28GMaF-HEH60pvhNMN-Gif0tffG2j3GGGiazrzfURAivljwvEVygcS6Zk1ZyIojWaG5LLZow8ubZYtYVSDB5rJmray3aMVqdstbXjeorBArpOBNzqvWJdrSxQZtynaJmnxZfperZc2rkn1GNW_WwuUWtbxFDCX-hvNv16iQ67ng_lyUVXGNVoLlfC79XFZtLYXgBWradbF9673qu9Gad3_jlbde8DZf-kLelDkTviZAwCc9xBndge57yGgC2ADuksQtow9j6Hd9FGtiIjAhjbIU6xAoxRTIj04nmXvhlffxUvd-Oj6cjH1Ud4PVZhy7gzmerII0xjRJCQWHfniG7o-n6eC6c1QEFJMYsKPIhdLT0drJ9Op-Gu666UkBVmf71F6d7VNn-xTOlLPPib5cRMaN-mswk7J6MAdtdsNk9KPaHYf_y78-k-txOAy6G3-aJ2P_taksUVg15_s4nwckIUSE0vAP66in_w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1841702510</pqid></control><display><type>article</type><title>4.3 EFFECT OF LURASIDONE ON BODY WEIGHT AND LABORATORY PARAMETERS IN ADOLESCENT PATIENTS WITH SCHIZOPHRENIA: RESULTS FROM A 6-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY</title><source>Applied Social Sciences Index &amp; Abstracts (ASSIA)</source><source>Access via ScienceDirect (Elsevier)</source><creator>Goldman, Robert S., PhD ; Robb, Adelaide S., MD ; Silva, Robert M., PhD ; Cucchiaro, Josephine B., PhD ; Deng, Ling, PhD ; Loebel, Antony, MD</creator><creatorcontrib>Goldman, Robert S., PhD ; Robb, Adelaide S., MD ; Silva, Robert M., PhD ; Cucchiaro, Josephine B., PhD ; Deng, Ling, PhD ; Loebel, Antony, MD</creatorcontrib><description>Objectives: To evaluate the effect of short-term treatment with lurasidone on body weight, metabolic parameters, and prolactin levels in adolescent patients with schizophrenia. Methods: In a multicenter, placebo-controlled study, adolescents (13-17 years old) with schizophrenia (DSM-IV-TR criteria) were randomly assigned to 6 weeks of double-blind treatment with fixed-dose lurasidone 40 mg/d, 80 mg/d, or placebo. Safety analyses included change from baseline to week 6 in body weight (mixed-model repeated-measures analysis) and laboratory parameters (rank analysis ofcovariance [ANCOVA] with the last observation carried forward[LOCF]). Results: A total of 326 patients (mean age=15.4 years) were randomized and received lurasidone 40 mg/d (N=108), 80 mg/d (N=106), or placebo (N=112). Least-squares mean change in weight at week 6 for the lurasidone 40 mg/d, 80 mg/d, and placebo groups was 0.17 kg, 0.49 kg, and 0.05 kg, respectively. Median change at week 6 (LOCF) in total cholesterol (overall) was -4.0 mg/dL, -2.0 mg/dL, and -7.0 mg/dL, respectively; in triglycerides was -2.0 mg/dL, 7.0 mg/dL, and -2.0 mg/dL, respectively; and in glucose was 0.0 mg/dL, 1.0 mg/dL, and 0.0 mg/dL, respectively. Median change in prolactin level at week 6 (LOCF) in male patients was 0.8 ng/mL, 1.0 ng/mL, and 0.0 ng/mL for the lurasidone 40 mg/d, 80 mg/d, and placebo groups, respectively; and in female patients was 0.6 ng/mL, 4.4 ng/mL, and 0.7 ng/mL, respectively. Conclusions: Lurasidone was not associated with clinically meaningful effects on body weight, lipids, glucose, or prolactin in this placebo-controlled trial involving adolescent patients with acute schizophrenia. These findings require confirmation in longer-term studies, they but provide support for the safety of lurasidone as a potential treatment for adolescents with schizophrenia. Longer-term, open-label safety data are currently being collected.</description><identifier>ISSN: 0890-8567</identifier><identifier>EISSN: 1527-5418</identifier><identifier>DOI: 10.1016/j.jaac.2016.09.198</identifier><identifier>CODEN: JAAPEE</identifier><language>eng</language><publisher>Baltimore: Elsevier Inc</publisher><subject>Adolescents ; Body weight ; Child &amp; adolescent psychiatry ; Cholesterol ; Clinical trials ; Glucose ; Lipids ; Mental disorders ; Parameters ; Patients ; Pediatrics ; Physiological psychology ; Placebo effect ; Prolactin ; Psychiatry ; Psychopharmacology ; Psychotropic drugs ; Safety ; Schizophrenia ; Therapeutic applications ; Triglycerides</subject><ispartof>Journal of the American Academy of Child and Adolescent Psychiatry, 2016-10, Vol.55 (10), p.S163-S163</ispartof><rights>2016</rights><rights>Copyright Lippincott Williams &amp; Wilkins Oct 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jaac.2016.09.198$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,782,786,3552,27931,27932,31006,46002</link.rule.ids></links><search><creatorcontrib>Goldman, Robert S., PhD</creatorcontrib><creatorcontrib>Robb, Adelaide S., MD</creatorcontrib><creatorcontrib>Silva, Robert M., PhD</creatorcontrib><creatorcontrib>Cucchiaro, Josephine B., PhD</creatorcontrib><creatorcontrib>Deng, Ling, PhD</creatorcontrib><creatorcontrib>Loebel, Antony, MD</creatorcontrib><title>4.3 EFFECT OF LURASIDONE ON BODY WEIGHT AND LABORATORY PARAMETERS IN ADOLESCENT PATIENTS WITH SCHIZOPHRENIA: RESULTS FROM A 6-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY</title><title>Journal of the American Academy of Child and Adolescent Psychiatry</title><description>Objectives: To evaluate the effect of short-term treatment with lurasidone on body weight, metabolic parameters, and prolactin levels in adolescent patients with schizophrenia. Methods: In a multicenter, placebo-controlled study, adolescents (13-17 years old) with schizophrenia (DSM-IV-TR criteria) were randomly assigned to 6 weeks of double-blind treatment with fixed-dose lurasidone 40 mg/d, 80 mg/d, or placebo. Safety analyses included change from baseline to week 6 in body weight (mixed-model repeated-measures analysis) and laboratory parameters (rank analysis ofcovariance [ANCOVA] with the last observation carried forward[LOCF]). Results: A total of 326 patients (mean age=15.4 years) were randomized and received lurasidone 40 mg/d (N=108), 80 mg/d (N=106), or placebo (N=112). Least-squares mean change in weight at week 6 for the lurasidone 40 mg/d, 80 mg/d, and placebo groups was 0.17 kg, 0.49 kg, and 0.05 kg, respectively. Median change at week 6 (LOCF) in total cholesterol (overall) was -4.0 mg/dL, -2.0 mg/dL, and -7.0 mg/dL, respectively; in triglycerides was -2.0 mg/dL, 7.0 mg/dL, and -2.0 mg/dL, respectively; and in glucose was 0.0 mg/dL, 1.0 mg/dL, and 0.0 mg/dL, respectively. Median change in prolactin level at week 6 (LOCF) in male patients was 0.8 ng/mL, 1.0 ng/mL, and 0.0 ng/mL for the lurasidone 40 mg/d, 80 mg/d, and placebo groups, respectively; and in female patients was 0.6 ng/mL, 4.4 ng/mL, and 0.7 ng/mL, respectively. Conclusions: Lurasidone was not associated with clinically meaningful effects on body weight, lipids, glucose, or prolactin in this placebo-controlled trial involving adolescent patients with acute schizophrenia. These findings require confirmation in longer-term studies, they but provide support for the safety of lurasidone as a potential treatment for adolescents with schizophrenia. Longer-term, open-label safety data are currently being collected.</description><subject>Adolescents</subject><subject>Body weight</subject><subject>Child &amp; adolescent psychiatry</subject><subject>Cholesterol</subject><subject>Clinical trials</subject><subject>Glucose</subject><subject>Lipids</subject><subject>Mental disorders</subject><subject>Parameters</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Physiological psychology</subject><subject>Placebo effect</subject><subject>Prolactin</subject><subject>Psychiatry</subject><subject>Psychopharmacology</subject><subject>Psychotropic drugs</subject><subject>Safety</subject><subject>Schizophrenia</subject><subject>Therapeutic applications</subject><subject>Triglycerides</subject><issn>0890-8567</issn><issn>1527-5418</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>7QJ</sourceid><recordid>eNp9ks-K2zAQxk1poem2L9CToJce1q5G_iO7lIJiKxtTrRVsh5BehKvI4NSb7Fqbwr5Sn7IKKRT2UHQYwfy-YWa-8bz3gAPAkHzaB_uu0wFx_wBnAWTpC28GMaF-HEH60pvhNMN-Gif0tffG2j3GGGiazrzfURAivljwvEVygcS6Zk1ZyIojWaG5LLZow8ubZYtYVSDB5rJmray3aMVqdstbXjeorBArpOBNzqvWJdrSxQZtynaJmnxZfperZc2rkn1GNW_WwuUWtbxFDCX-hvNv16iQ67ng_lyUVXGNVoLlfC79XFZtLYXgBWradbF9673qu9Gad3_jlbde8DZf-kLelDkTviZAwCc9xBndge57yGgC2ADuksQtow9j6Hd9FGtiIjAhjbIU6xAoxRTIj04nmXvhlffxUvd-Oj6cjH1Ud4PVZhy7gzmerII0xjRJCQWHfniG7o-n6eC6c1QEFJMYsKPIhdLT0drJ9Op-Gu666UkBVmf71F6d7VNn-xTOlLPPib5cRMaN-mswk7J6MAdtdsNk9KPaHYf_y78-k-txOAy6G3-aJ2P_taksUVg15_s4nwckIUSE0vAP66in_w</recordid><startdate>20161001</startdate><enddate>20161001</enddate><creator>Goldman, Robert S., PhD</creator><creator>Robb, Adelaide S., MD</creator><creator>Silva, Robert M., PhD</creator><creator>Cucchiaro, Josephine B., PhD</creator><creator>Deng, Ling, PhD</creator><creator>Loebel, Antony, MD</creator><general>Elsevier Inc</general><general>Elsevier BV</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope><scope>7TK</scope><scope>K9.</scope></search><sort><creationdate>20161001</creationdate><title>4.3 EFFECT OF LURASIDONE ON BODY WEIGHT AND LABORATORY PARAMETERS IN ADOLESCENT PATIENTS WITH SCHIZOPHRENIA: RESULTS FROM A 6-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY</title><author>Goldman, Robert S., PhD ; Robb, Adelaide S., MD ; Silva, Robert M., PhD ; Cucchiaro, Josephine B., PhD ; Deng, Ling, PhD ; Loebel, Antony, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2121-2f1597d1cff197610e10a66152f351fdf45c2e41e374980c31770712bac696963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adolescents</topic><topic>Body weight</topic><topic>Child &amp; adolescent psychiatry</topic><topic>Cholesterol</topic><topic>Clinical trials</topic><topic>Glucose</topic><topic>Lipids</topic><topic>Mental disorders</topic><topic>Parameters</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Physiological psychology</topic><topic>Placebo effect</topic><topic>Prolactin</topic><topic>Psychiatry</topic><topic>Psychopharmacology</topic><topic>Psychotropic drugs</topic><topic>Safety</topic><topic>Schizophrenia</topic><topic>Therapeutic applications</topic><topic>Triglycerides</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Goldman, Robert S., PhD</creatorcontrib><creatorcontrib>Robb, Adelaide S., MD</creatorcontrib><creatorcontrib>Silva, Robert M., PhD</creatorcontrib><creatorcontrib>Cucchiaro, Josephine B., PhD</creatorcontrib><creatorcontrib>Deng, Ling, PhD</creatorcontrib><creatorcontrib>Loebel, Antony, MD</creatorcontrib><collection>CrossRef</collection><collection>Applied Social Sciences Index &amp; Abstracts (ASSIA)</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><jtitle>Journal of the American Academy of Child and Adolescent Psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Goldman, Robert S., PhD</au><au>Robb, Adelaide S., MD</au><au>Silva, Robert M., PhD</au><au>Cucchiaro, Josephine B., PhD</au><au>Deng, Ling, PhD</au><au>Loebel, Antony, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>4.3 EFFECT OF LURASIDONE ON BODY WEIGHT AND LABORATORY PARAMETERS IN ADOLESCENT PATIENTS WITH SCHIZOPHRENIA: RESULTS FROM A 6-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY</atitle><jtitle>Journal of the American Academy of Child and Adolescent Psychiatry</jtitle><date>2016-10-01</date><risdate>2016</risdate><volume>55</volume><issue>10</issue><spage>S163</spage><epage>S163</epage><pages>S163-S163</pages><issn>0890-8567</issn><eissn>1527-5418</eissn><coden>JAAPEE</coden><abstract>Objectives: To evaluate the effect of short-term treatment with lurasidone on body weight, metabolic parameters, and prolactin levels in adolescent patients with schizophrenia. Methods: In a multicenter, placebo-controlled study, adolescents (13-17 years old) with schizophrenia (DSM-IV-TR criteria) were randomly assigned to 6 weeks of double-blind treatment with fixed-dose lurasidone 40 mg/d, 80 mg/d, or placebo. Safety analyses included change from baseline to week 6 in body weight (mixed-model repeated-measures analysis) and laboratory parameters (rank analysis ofcovariance [ANCOVA] with the last observation carried forward[LOCF]). Results: A total of 326 patients (mean age=15.4 years) were randomized and received lurasidone 40 mg/d (N=108), 80 mg/d (N=106), or placebo (N=112). Least-squares mean change in weight at week 6 for the lurasidone 40 mg/d, 80 mg/d, and placebo groups was 0.17 kg, 0.49 kg, and 0.05 kg, respectively. Median change at week 6 (LOCF) in total cholesterol (overall) was -4.0 mg/dL, -2.0 mg/dL, and -7.0 mg/dL, respectively; in triglycerides was -2.0 mg/dL, 7.0 mg/dL, and -2.0 mg/dL, respectively; and in glucose was 0.0 mg/dL, 1.0 mg/dL, and 0.0 mg/dL, respectively. Median change in prolactin level at week 6 (LOCF) in male patients was 0.8 ng/mL, 1.0 ng/mL, and 0.0 ng/mL for the lurasidone 40 mg/d, 80 mg/d, and placebo groups, respectively; and in female patients was 0.6 ng/mL, 4.4 ng/mL, and 0.7 ng/mL, respectively. Conclusions: Lurasidone was not associated with clinically meaningful effects on body weight, lipids, glucose, or prolactin in this placebo-controlled trial involving adolescent patients with acute schizophrenia. These findings require confirmation in longer-term studies, they but provide support for the safety of lurasidone as a potential treatment for adolescents with schizophrenia. Longer-term, open-label safety data are currently being collected.</abstract><cop>Baltimore</cop><pub>Elsevier Inc</pub><doi>10.1016/j.jaac.2016.09.198</doi></addata></record>
fulltext fulltext
identifier ISSN: 0890-8567
ispartof Journal of the American Academy of Child and Adolescent Psychiatry, 2016-10, Vol.55 (10), p.S163-S163
issn 0890-8567
1527-5418
language eng
recordid cdi_proquest_miscellaneous_1850768271
source Applied Social Sciences Index & Abstracts (ASSIA); Access via ScienceDirect (Elsevier)
subjects Adolescents
Body weight
Child & adolescent psychiatry
Cholesterol
Clinical trials
Glucose
Lipids
Mental disorders
Parameters
Patients
Pediatrics
Physiological psychology
Placebo effect
Prolactin
Psychiatry
Psychopharmacology
Psychotropic drugs
Safety
Schizophrenia
Therapeutic applications
Triglycerides
title 4.3 EFFECT OF LURASIDONE ON BODY WEIGHT AND LABORATORY PARAMETERS IN ADOLESCENT PATIENTS WITH SCHIZOPHRENIA: RESULTS FROM A 6-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T08%3A23%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=4.3%20EFFECT%20OF%20LURASIDONE%20ON%20BODY%20WEIGHT%20AND%20LABORATORY%20PARAMETERS%20IN%20ADOLESCENT%20PATIENTS%20WITH%20SCHIZOPHRENIA:%20RESULTS%20FROM%20A%206-WEEK,%20DOUBLE-BLIND,%20PLACEBO-CONTROLLED%20STUDY&rft.jtitle=Journal%20of%20the%20American%20Academy%20of%20Child%20and%20Adolescent%20Psychiatry&rft.au=Goldman,%20Robert%20S.,%20PhD&rft.date=2016-10-01&rft.volume=55&rft.issue=10&rft.spage=S163&rft.epage=S163&rft.pages=S163-S163&rft.issn=0890-8567&rft.eissn=1527-5418&rft.coden=JAAPEE&rft_id=info:doi/10.1016/j.jaac.2016.09.198&rft_dat=%3Cproquest_cross%3E1850768271%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1841702510&rft_id=info:pmid/&rft_els_id=1_s2_0_S0890856716314277&rfr_iscdi=true